Meeting of Pars Isotope Company and Cancer Specialty Associations; Synergy for Advancing Novel Therapies

Pars Isotope Company will hold a joint meeting of the country’s Nuclear Medicine, Radio-Oncology, Hematology, and Oncology associations on December 25, 2025, at Shohadaye Tajrish Hospital.

This meeting is designed with the aim of creating scientific synergy among disciplines related to cancer diagnosis and treatment, reviewing the latest clinical and research achievements, and providing a platform for the exchange of experience among the country’s prominent specialists. Given the central role of Pars Isotope as the sole entity responsible for producing radiopharmaceuticals in Iran, the company’s involvement in organizing such events is considered an effective step in developing treatments based on nuclear medicine.

Meeting Axes:

Radiopharmaceuticals; A New Horizon in Cancer Diagnosis and Treatment

Diagnostic and Therapeutic Applications of FAPI

Novel Cancer Therapies in Radio-Oncology

Alpha Therapy; Biology and Therapeutic Application

 

Target Groups:

Specialists in Nuclear Medicine, Hematology and Oncology, Radiation Oncology, and researchers in the field of cancer.

 

Registration:

This meeting grants retraining credits for participants. The registration process is conducted exclusively through the website of the National Continuous Education Platform under registration number 267354.

 

Time and Venue:

Monday, December 25, 2025, from 8:00 AM to 4:00 PM

Tehran, Shohadaye Tajrish Hospital, New Building, First Floor, Conference Hall